MATERNAL AND PERINATAL OUTCOMES IN WOMEN WITH PCOS RECEIVING METFORMIN DURING PREGNANCY: A CLINICAL OBSERVATIONAL STUDY

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. It is often associated with infertility, insulin resistance, and pregnancy complications. Metformin, an insulin-sensitizing agent, is frequently used to manage PCOS and has shown potential benefits during pregnancy. This study evaluates the maternal and perinatal outcomes in pregnant women with PCOS.
Objective: The study compares the maternal and perinatal outcomes in pregnant women with PCOS receiving metformin pre-pregnancy and throughout pregnancy with those in low risk healthy pregnant women.
Methods: This is a comparative study conducted over two years on pregnant women with PCOS who conceived on Metformin and continued it throughout pregnancy. The study compares pregnant women having PCOS who conceived on metformin and continued it throughout their pregnancy. Those patients were compared with low risk healthy pregnant women. Maternal and perinatal outcomes were assessed.
Results: There was no statistically significant difference between the miscarriage rates among the PCOS group (4.9%) and controls (6.0%) (p=0.679). Maternal complications like GDM, PIH, and polyhydramnios showed no significant differences between the study groups as well. However, preterm delivery was found to be significantly lower in the Metformin-treated PCOS group (14.7%) compared to controls (24.1%) (p=0.048). Other outcomes, including IUD and maternal hypoglycemia, were comparable between the study groups.
Conclusion: Present study concludes that the use of metformin throughout pregnancy in women with PCOS lowers the rate of preterm delivery without increasing the risk of miscarriage or other maternal and neonatal complications. It suggests that it may be a safe and beneficial option for improving pregnancy outcomes in this population.